Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients

New erythropoiesis‐stimulating agents with a longer half‐life have been developed for the treatment of anemia in patients with end‐stage renal disease. This study evaluated the efficacy of darbepoetin alfa (DA) and long‐acting epoetin beta pegol (continuous erythropoietin receptor activator, CERA) i...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic apheresis and dialysis 2015-10, Vol.19 (5), p.450-456
Main Authors: Washida, Naoki, Inoue, Shuji, Kasai, Takahiro, Shinozuka, Keisuke, Hosoya, Koji, Morimoto, Kohkichi, Wakino, Shu, Hayashi, Koichi, Itoh, Hiroshi
Format: Article
Language:English
Subjects:
Blood pressure
Blood Pressure - drug effects
Darbepoetin alfa
Darbepoetin alfa - administration & dosage
Darbepoetin alfa - pharmacology
Darbepoetin alfa - therapeutic use
Epoetin beta pegol
Erythropoietin - administration & dosage
Erythropoietin - pharmacology
Erythropoietin - therapeutic use
Female
Ferritins - blood
Hematinics - administration & dosage
Hematinics - pharmacology
Hematinics - therapeutic use
Hemoglobins - analysis
Humans
Iron - metabolism
Iron utilization
Male
Middle Aged
Peritoneal Dialysis
Polyethylene Glycols - administration & dosage
Polyethylene Glycols - pharmacology
Polyethylene Glycols - therapeutic use
Receptors, Erythropoietin
Transferrin - analysis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:New erythropoiesis‐stimulating agents with a longer half‐life have been developed for the treatment of anemia in patients with end‐stage renal disease. This study evaluated the efficacy of darbepoetin alfa (DA) and long‐acting epoetin beta pegol (continuous erythropoietin receptor activator, CERA) in patients on peritoneal dialysis (PD). Twenty‐nine patients who had undergone PD for at least 6 months and were iron replacement‐naïve and negative for inflammatory parameters were enrolled. Hemoglobin (Hgb) levels and blood pressure were evaluated before and after switching from DA to CERA. Percent transferrin saturation (TSAT), serum ferritin levels and blood pressure were also assessed. Twenty‐eight patients were subject to the analysis, excluding one patient with a decrease in Hgb by ≥10%. Switching from DA to CERA did not alter Hgb levels. The doses of DA and CERA after 12 month treatment of each agent were 118.48 ± 79.63 and 89.88 ± 47.50 μg/4 weeks, respectively (conversion ratio, 1:0.76). The CERA dose administered during the final 6 months was abated, compared with that given during the initial 6 months (P = 0.035). The frequency of CERA injection over a 12‐month period was less than that of DA (10.0 ± 3.0 vs. 16.4 ± 5.0, P 
ISSN:1744-9979
1744-9987
DOI:10.1111/1744-9987.12306